PrEP

Gilead plans European trial of twice-yearly HIV PrEP drug
Gilead plans European trial of twice-yearly HIV PrEP drug
Pharmaphorum
Gilead Sciences
clinical trials
HIV
PrEP
Sunlenca
Europe
Flag link:
ViiV Healthcare receives European Commission approval for Apretude
ViiV Healthcare receives European Commission approval for Apretude
Pharmaceutical Business Review
ViiV Healthcare
Europe
Apretude
HIV
AIDS
PrEP
Flag link:
Medicare proposes coverage for PrEP without patient cost sharing
Medicare proposes coverage for PrEP without patient cost sharing
Fierce Healthcare
Medicare
CMS
HIV
PrEP
Flag link:
Gilead, US government set for courtroom showdown over PrEP drug patents
Gilead, US government set for courtroom showdown over PrEP drug patents
Fierce Pharma
Gilead Sciences
legal
patents
Truvada
Descovey
PrEP
Flag link:
Federal claims court rules in favor of Gilead in CDC Truvada patent case
Federal claims court rules in favor of Gilead in CDC Truvada patent case
Endpoints
Gilead Sciences
Truvada
PrEP
HIV
CDC
patents
Flag link:
Judge invalidates parts of the ACA that mandate health coverage of many preventive services and drugs
Judge invalidates parts of the ACA that mandate health coverage of many preventive services and drugs
Stat
ACA
legal HIV
PrEP
insurance
Flag link:
GSK, still early in US launch, licenses long-acting HIV PrEP drug Apretude to patent pool for poorer nations
GSK, still early in US launch, licenses long-acting HIV PrEP drug Apretude to patent pool for poorer nations
Fierce Pharma
GSK
HIV
PrEP
Apretude
Medicines Patent Pool
Flag link:
'Who wants to make money?' Court documents outline wild fraud scheme targeting Gilead HIV meds
'Who wants to make money?' Court documents outline wild fraud scheme targeting Gilead HIV meds
Fierce Pharma
Gilead Sciences
legal
fraud
HIV
PrEP
Flag link:
Gilead presses HIV drug fraud in court, wins freeze of 'kingpin' assets
Gilead presses HIV drug fraud in court, wins freeze of 'kingpin' assets
Fierce Pharma
Gilead Sciences
fraud
HIV
PrEP
Truvada
Descovy
Flag link:
FDA clears first long-acting HIV-prevention injectable, giving ViiV claim to historic OK
FDA clears first long-acting HIV-prevention injectable, giving ViiV claim to historic OK
Endpoints
FDA
HIV
PrEP
Apretude
GSK
ViiV Healthcare
Flag link:
Digital pill tracks HIV PrEP adherence with 98% accuracy
Digital pill tracks HIV PrEP adherence with 98% accuracy
Pharmaforum
digital pills
HIV
PrEP
Gilead Sciences
Flag link:
GSK's ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms
GSK's ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms
Fierce Pharma
ViiV Healthcare
GSK
HIV
PrEP
cabotegravir
Flag link:
Mid-Study Peek at Merck's Once-A-Month HIV Preventative Shows Promise
Mid-Study Peek at Merck's Once-A-Month HIV Preventative Shows Promise
BioSpace
Merck
HIV
clinical trials
islatravir
PrEP
Flag link:
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma
pharma marketing
drug pricing
COVID-19
pandemic
remdesivir
Gilead Sciences
HIV
PrEP
Pfizer
Flag link:
GSK and ViiV score breakthrough therapy designation in HIV prevention, as Truvada showdown draws nearer
GSK and ViiV score breakthrough therapy designation in HIV prevention, as Truvada showdown draws nearer
Endpoints
GSK
ViiV
FDA
cabotegravir
HIV
PrEP
Flag link:
GSK reports its long-acting HIV PrEP tops Gilead's Truvada — again
GSK reports its long-acting HIV PrEP tops Gilead's Truvada — again
Endpoints
GSK
ViiV
cabotegravir
HIV
PrEP
FDA
Flag link:
Gilead got a boost from a newly approved PrEP drug. Now, a major insurer is dropping coverage
Gilead got a boost from a newly approved PrEP drug. Now, a major insurer is dropping coverage
MedCity News
Gilead Sciences
UnitedHealthcare
PrEP
HIV
Descovy
Truvada
Flag link:
Life-Saving HIV Drug PrEP On NHS Delayed Amid Coronavirus Pandemic
Life-Saving HIV Drug PrEP On NHS Delayed Amid Coronavirus Pandemic
Forbes
HIV
NHS
PrEP
pandemic
COVID-19
Flag link:
GSK sub’s injectable outperforms Gilead in late-stage PrEP trial
GSK sub’s injectable outperforms Gilead in late-stage PrEP trial
Endpoints
GSK
Gilead Sciences
HIV
PrEP
Truvada
ViiV Healthcare
cabotegravir
Flag link:
More threat to Gilead's HIV business? GlaxoSmithKline touts long-acting injectable PrEP win against Truvada
More threat to Gilead's HIV business? GlaxoSmithKline touts long-acting injectable PrEP win against Truvada
Fierce Pharma
GSK
Gilead Sciences
Truvada
cabotegravir
HIV
PrEP
Flag link:

Pages